Grounded in science, we explore and validate novel targets with rigor and resolve, paving the way toward breakthrough therapies for immunological diseases and cancer.

We are taking a novel approach to targeting SIRP

Our portfolio of Signal Regulatory Proteins (SIRP)-directed antibodies work via a unique mechanism of action and have the potential to address the underlying pathology across a broad range of diseases.

We are committed to tackling therapeutic challenges in areas with critical unmet needs and empowering patients with breakthrough treatments.


Our innovative team has what it takes to drive transformational impact.